We observed that anti-CD8 antibody treatment not only eliminated the difference in tumor growth between SENP3-WT and SENP3–9A MC38 tumor mice, but also increased tumor growth in both tumor models as compared to non-injected controls (Figs. 1F and S1C), suggesting that activating mitotic SENP3 in tumors can promote host CD8+ T cell-mediated anti-tumor immunity. Here, CD8A is linked to neoplasm.